References
- Alexandrov AV, Black SE, Ehrlich LE, et al. Predictors of hemorrhagic transformation occurring spontaneously and on anticoagulants in patients with acute ischemic stroke. Stroke 1997; 28: 1198–1202
- Bowes MP, Zivin JA, Thomas GR, et al. Acute hypertension, butnot thrombolysis, increases the incidence and severity of hemor-rhagic transformation following experimental stroke in rabbits. Exp Neurol 1996; 141: 40–46
- del Zoppo GJ, Copeland BR, Anderchek K, et al. Hemorrhagic transformation following tissue plasminogen activator in experi-mental cerebral infarction. Stroke 1990; 21: 596–601
- Aoki T, Sumii T, Mori T, et al. Blood—brain barrier disruption andmatrix metalloproteinase-9 expression during reperfusion injury: Mechanical versus embolic focal ischemia in spontaneously hypertensive rats. Stroke 2002; 33: 2711–2717
- Hu K, Yang J, Tanaka S, et al. Tissue-type plasminogen activatoracts as a cytokine that triggers intracellular signal transduction and induces matrix metalloproteinase-9 gene expression. J Biol Chem 2006; 281: 2120–2127
- Kahles T, Foerch C, Sitzer M, et al. Tissue plasminogen activator mediated blood—brain barrier damage in transient focal cerebral ischemia in rats: Relevance of interactions between thrombotic material and thrombolytic agent. Vase Pharmaeol 2005; 43: 254–259
- Pfefferkorn T, Rosenberg GA. Closure of the blood—brain barrierby matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion. Stroke 2003; 34: 2025–2030
- Wang X, Lee SR, Arai K, et al. Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med 2003; 9: 1313–1317
- Asahi M, Wang X, Mori T, et al. Effects of matrix metallopro-teinase-9 gene knock-out on the proteolysis of blood—brain barrier and white matter components after cerebral ischemia. J Neurosci 2001; 21: 7724–7732
- Aoki T, Sumii T, Mori T, et al. Blood—brain barrier disruption and matrix metalloproteinase-9 expression during reperfusion injury: Mechanical versus embolic focal ischemia in spontaneously hypertensive rats. Stroke 2002; 33: 2711–2717
- Benchenane K, Berezowski V, Ali C, et al. Tissue-type plasmino-gen activator crosses the intact blood—brain barrier by low-density lipoprotein receptor-related protein-mediated transcytosis. Circulation 2005; 111: 2241–2249
- Wang YF, Tsirka SE, Strickland S, et al. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med 1998; 4: 228–231
- Pekelharing HL, Kleinveld HA, Duif PF, et al. Effect of lipoprotein(a) and LDL on plasminogen binding to extracellular matrix and on matrix-dependent plasminogen activation by tissue plasminogen activator. Thromb Haemost 1996; 75: 497–502
- Hu K, Yang J, Tanaka S, et al. Tissue-type plasminogen activator acts as a cytokine that triggers intracellular signal transduction and induces matrix metalloproteinase-9 gene expression. J Biol Chem 2006; 281: 2120–2127
- Yang DY, Pan HC, Chen CJ, et al. Effects of tissue plasminogen activator on cerebral microvessels of rats during focal cerebral ischemia and reperfusion. Neurol Res 2007; 29: 274–282
- Horwood JM, Ripley TL, Stephens DN. Evidence for disrupted NMDA receptor function in tissue plasminogen activator knock-out mice. Behav Brain Res 2004; 150: 127–138.
- Fagan SC, Nagaraja TN, Fenstermacher JD, et al. Hemorrhagic transformation is related to the duration of occlusion and treatment with tissue plasminogen activator in a nonembolic stroke model. Neurol Res 2003; 25: 377–382
- Zhang W, Sato K, Hayashi T, et al. Extension of ischemic therapeutic time window by a free radical scavenger, Edaravone, reperfused with tPA in rat brain. Neurol Res 2004; 26: 342–348.